SELLAS Says Arbitrator Dismisses Its Claims Against 3D Medicines, Orders SELLAS To Pay Approximately $1M In Legal Fees
Sellas Life Sciences Group Inc SLS
$10.01
▼ -2.72%
($-0.28)
🔥 High Short Interest
🎢 High Beta
🗓️ Earnings Next Week
Open
$10.37
Prev Close
$10.29
Day Range
$9.87 – $10.54
52W Range
$1.39 – $15.88
Market Cap
$1.86B
Beta
2.50
EPS (TTM)
$-0.23
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2008-03-12 |
| Shares Out. | 196,630,000 |
| Website | sellaslifesciences.com/ ↗ |
| Phone | 16462005278 |
| Employees | 13 |
| Net Income | -$8.4M |
| Total Assets | $114.2M |
| Total Liabilities | $6.8M |
| Equity | $107.4M |
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Sellas Life Sciences Group Inc is a publicly traded company under the ticker symbol SLS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)